$5.77
1.70%
Nasdaq, Jan 02, 10:00 pm CET
ISIN
US1856341029
Symbol
CLNN

Clene Inc Stock price

$5.77
-3.49 37.69% 1M
+1.82 46.08% 6M
-0.10 1.70% YTD
+0.38 7.05% 1Y
-14.23 71.15% 3Y
-145.63 96.19% 5Y
-187.23 97.01% 10Y
-187.23 97.01% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
-0.10 1.70%
ISIN
US1856341029
Symbol
CLNN
Industry

Key metrics

Basic
Market capitalization
$59.6m
Enterprise Value
$68.8m
Net debt
$9.1m
Cash
$7.9m
Shares outstanding
10.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
283.9 | 402.6
EV/Sales
327.4 | 464.2
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-32.4%
Return on Equity
444.9%
ROCE
-174.7%
ROIC
-
Debt/Equity
-1.4
Financials (TTM | estimate)
Revenue
$210.0k | $148.1k
EBITDA
$-22.9m | $-21.3m
EBIT
$-24.5m | $-22.2m
Net Income
$-30.5m | $-24.2m
Free Cash Flow
$-18.6m
Growth (TTM | estimate)
Revenue
-50.0% | -56.4%
EBITDA
29.9% | 32.2%
EBIT
28.8% | 33.0%
Net Income
15.3% | 38.5%
Free Cash Flow
21.4%
Margin (TTM | estimate)
Gross
82.2%
EBITDA
-10,708.9% | -14,393.9%
EBIT
-11,428.5%
Net
-14,250.5% | -16,364.7%
Free Cash Flow
-8,702.8%
More
EPS
$-3.0
FCF per Share
$-1.8
Short interest
8.4%
Employees
76
Rev per Employee
$0.0
Show more

Is Clene Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Clene Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Clene Inc forecast:

12x Buy
92%
1x Hold
8%

Analyst Opinions

13 Analysts have issued a Clene Inc forecast:

Buy
92%
Hold
8%

Financial data from Clene Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
0.21 0.21
50% 50%
100%
- Direct Costs 0.04 0.04
56% 56%
19%
0.18 0.18
45% 45%
86%
- Selling and Administrative Expenses 10 10
24% 24%
4,833%
- Research and Development Expense 15 15
24% 24%
7,143%
-23 -23
30% 30%
-10,914%
- Depreciation and Amortization 1.54 1.54
7% 7%
733%
EBIT (Operating Income) EBIT -24 -24
29% 29%
-11,646%
Net Profit -31 -31
15% 15%
-14,524%

In millions USD.

Don't miss a Thing! We will send you all news about Clene Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Clene Inc Stock News

Neutral
GlobeNewsWire
27 days ago
SALT LAKE CITY, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (...
Neutral
GlobeNewsWire
about one month ago
FDA recommended biomarker analyses show statistically significant reductions in NfL and GFAP in participants treated with CNM-Au8 Biomarker improvements are strongly associated with longer survival, reinforcing CNM-Au8's potential disease modifying activity Company has requested a Type C meeting in the first quarter of 2026 to present the newly completed analyses supporting a planned NDA submis...
Neutral
GlobeNewsWire
about one month ago
SALT LAKE CITY, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced it plans provi...
More Clene Inc News

Company Profile

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutics for neurodegenerative diseases. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded on August 12, 2020 and is headquartered in Salt Lake City, UT.

Head office United States
CEO Robert Etherington
Employees 76
Founded 2013
Website clene.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today